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CHAPTER ONE: INTRODUCTION 
1. 1 Background 
Diabetes mellitus has been defined as a condition characterized by hyperglycemia resulting 
from defects in insulin secretion from the pancreas or the body’s inability to use insulin correctly 
(American Diabetes Association, 2009). The most common form of diabetes is type 2 diabetes 
mellitus (T2DM) which is typically associated with insulin resistance. T2DM affects 
approximately 90% to 95% of patients diagnosed with diabetes (Olokoba, Obateru, & Olokoba, 
2012). 
Among patients with T2DM, adherence to antihyperglycemic medication is a major 
contributor to achieving adequate glycemic control (Lau & Nau, 2004). Pharmacotherapy for 
T2DM management (e.g., sulfonylureas, biguanides) can play a vital role in controlling symptoms 
and preventing complications, but non-adherence of antihyperglycemic medications is highly 
prevalent (Blackburn, Swidrovich, & Lemstra, 2013). Non-adherence of antihyperglycemic 
medications has been linked to increases in morbidity, mortality, and health care costs (Bagonza, 
Rutebemberwa, & Bazeyo, 2015). Non-adherence can also lead to micro vascular and macro 
vascular complications (Cziraky et al., 2015).  
Opioid analgesics are a class of medication used for the management of pain and cough. 
Some of the most common prescription opioids used for the management of pain are oxycodone, 
hydrocodone, and morphine (National Institue of Health, 2016). Prescription opioids  are also 
approved to treat cough (e.g., codeine) (Chung, 2005). Opioids produce analgesia by preventing 
the pain causing neurotransmitter release from the primary afferent terminals in the spinal cord, 
thus preventing the activation of inhibitory controls in the midbrain (Smith H.S., 2009).  
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Pain is associated with increased action in primary sensory neurons caused by an internal 
stimuli in the body (Dubin & Patapoutian, 2010). Chronic pain is a prevalent condition that impacts 
a patient’s daily activity and has a significant impact on the healthcare system (Butchart, Kerr, 
Heisler, Piette, & Krein, 2009). Chronic pain is often defined as any pain lasting more than 12 
weeks (e.g., low back pain, arthritis pain) (MedlinePlus, 2011). Approximately one-third of adults 
have chronic or acute pain and the prevalence of chronic pain increases with age (Volkow & 
McLellan, 2016). Additionally, 40% of the elderly suffer from chronic pain (Volkow & McLellan, 
2016). Chronic pain has also been linked to reduced quality of life, increased medical expenditures, 
and loss of employment (Butchart et al., 2009). 
 Patients with T2DM often have chronic pain due to other therapeutic conditions. Due to 
the high prevalence of chronic pain, prescription opioids are now the most commonly prescribed 
medications in the United States (Volkow & McLellan, 2016). Although, prescription opioids 
relieve pain, they have associated side effects when prescribed over long durations of time (e.g., 
over 3 months) (Berland & Rodgers, 2012; Volkow & McLellan, 2016). Prescription opioids are 
habit forming and their long-term use is linked with negative effects (Dr. Donald Teater, 2016). 
Furthermore, a lack of evidence supporting the long-term use of prescription opioids for pain 
management raises concern about the safety of these medications in T2DM patients (Noble et al., 
2010). According to the Substance Abuse and Mental Health Services Administration (SAMHSA) 
guidelines on chronic pain management, prescription opioid users are likely to fail to adhere to 
their other chronic treatment regimens and are at greater risk for  aberrant drug related behavior 
(ADRB) (Substance Abuse and Mental Health Services Administration, 2012). ADRBs are 
characterized by behavior that suggests controlled substance prescription overuse, addiction or 
abuse. Further, patients exhibiting ADRBs including actions such as falsification of prescriptions, 
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obtaining medications from non-medical sources, demanding more medication than prescribed, 
and resisting drug testing. Patients that demonstrate ADRBs can often become more interested in 
prescription opioids, as opposed to other medications (e.g., hypertension therapy) or in any other 
aspect of treatment. Therefore, patients with T2DM who are also prescribed prescription opioids 
may be at greater risk for poorer health outcomes associated with non-adherence of 
antihyperglycemic medications.  
 
1.2 Statement of Purpose  
The aims of this study are to understand the effect of prescription opioid use on 
antihyperglycemic medication adherence and the subsequent risk of developing diabetes related 
hospitalizations associated with non-adherence to antihyperglycemic medication, when both drugs 
are prescribed concomitantly.  
 
1.3 Statement of Problem 
Adherence to antihyperglycemic medication is a major factor in achieving adequate 
glycemic control. Chronic pain is a highly prevalent condition, as almost half of adults in the US 
with T2DM report acute and chronic pain (Francisco, 2012). Prescription opioids are the most 
prescribed class of medication for pain management with the number of prescriptions prescribed 
increased from 76 million in 1991 to 207 million in 2013 (Volkow & McLellan, 2016). Long-term 
use of prescription opioid is questionable as it can lead to adverse outcomes including ADRB 
patterns. Due to potential ADRBs, patients prescribed antihyperglycemics and prescription opioids 
concomitantly may be at risk for decreased adherence regarding their antihyperglycemic 
medication as these patients may become more focused on their prescription opioids rather than 
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other aspects of their treatment (Substance Abuse and Mental Health Services Administration, 
2012). Non-adherence of antihyperglycemic medications can lead to increased T2DM related 
complications and subsequent hospitalizations. 
 
1.4 Significance of Objectives 
Prescription opioids are a highly prescribed class of medication, which when administered 
over long durations can lead to negative effects (e.g., addiction, non-medical use).  Prescription 
opioids are often prescribed concomitantly with antihyperglycemic medication among patients 
with T2DM. Due to known associated negative effects of prescription opioids, it is imperative to 
study the impact of long term opioid use of antihyperglycemic medication when prescribed 
concomitantly.  Therefore, the primary aim of this study was to examine if there is any effect of 
long-term opioid use on antihyperglycemic medication adherence when the two medication classes 
are prescribed concomitantly among patients with T2DM. Additionally, this study also examined 
whether the duration of opioid use and antihyperglycemic adherence has any potential impact on 
subsequent diabetes related hospitalizations.  
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CHAPTER TWO: LITERATURE REVIEW 
2.1 Diabetes Mellitus 
Diabetes Mellitus (DM) is a metabolic disorder which is characterized by the presence of 
hyperglycemia, which is a condition in which excessive amount of glucose circulates in the blood 
plasma (Reaven, 1988). DM is attributed to defective insulin secretion in the body, defective 
insulin action or a combination of both (American Diabetes Association, 2009). Unmanaged 
chronic hyperglycemia, among patients with DM can lead to micro vascular and macro vascular 
complications affecting different parts of the human body including eyes, kidneys and nerves 
(Guariguata et al., 2014). 
DM is the most common metabolic disorders in the world and its prevalence has been 
increasing over the last two decades (Olokoba et al., 2012). Urbanization and its associated  
consequences are one of the prime reasons that has led to the increasing prevalence of DM. DM is 
the seventh leading cause of death in the US (Centers for Disease Control Prevention, 2011). 
According to the Centers for Disease Control and Prevention (CDC) estimates from the year 2014, 
found that 29.1 million Americans were diagnosed with diabetes, which accounted for 
approximately 9.3% of the US population (American Diabetes Association, 2012). According to 
2012 estimates, 1.4 million Americans are newly diagnosed with diabetes each year (American 
Diabetes Association, 2012). Incidence rates of DM are highest among non-Hispanic blacks and 
Hispanic adults (Centers for Disease Control and Prevention, 2014). 
 
2.2 Types of Diabetes Mellitus 
In the 1979, an international workgroup sponsored by the National Diabetes Data Group 
of the National Institutes of Health (NIH) developed the classification of DM based on the 
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recommendations of various diabetes organizations (American Diabetes Association, 1979). 
According to the American Diabetes Association guidelines of 2010, diabetes has been classified 
as detailed below (American Diabetes Association, 1979). 
Type 1 Diabetes Mellitus 
Type 1 DM (T1DM) is also reffered to as insulin dependent DM. T1DM accounts for only 
5–10% of those diagnosed with DM. It is more prevalent among children and young adults 
(American Diabetes Association, 1979). The etiology is associated with an autoimmune condition 
in the body. This autoimmune condition affects the ability of the pancreas to produce insulin 
naturally. Insulin is a hormone in the body that regulates the usage and storage of glucose and fat. 
A lack of insulin can lead to glucose build up in the blood, which would have otherwise been 
converted to energy and thus used by cells. 
 Type 2 Diabetes Mellitus 
Type 2 DM (T2DM) accounts for 90–95% of those diagnosed with DM. It is also known 
as adult-onset or noninsulin-dependent diabetes. The etiology is based on a combination of factors 
including resistance to insulin in the body, scarce insulin production by the pancreatic beta cells, 
and excessive glucagon secretion. As a result of inadequate insulin, the body is less able to absorb 
glucose from the blood. Patients with T2DM often do not require additional insulin throughout 
their lifetime (American Diabetes Association, 1979). 
 
2.3 Economic and Humanistic Impact of T2DM 
T2DM has a significant impact on the US healthcare system. In 2012, the total cost 
associated with T2DM was $245 billion, of which $176 billion was attributed to direct medical 
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costs and $69 billion was attributed to indirect medical costs (American Diabetes Association, 
2015). In 2012, there was a 41% increase in the direct medical costs of diabetes management from 
the year 2007, which was $174 billion (American Diabetes Association, 2013). Most of the 
increased costs associated with T2DM was seen among inpatient related care (43% of the total 
medical cost), prescriptions for managing T2DM related comorbidities (18%), antihyperglycemic 
prescription medications (12%), physician office visits (9%), and nursing facility stays (8%) 
(American Diabetes Association, 2015).  
Medical expenditures among diabetics are 2.3 times higher compared to patients without 
diabetes (American Diabetes Association, 2013). Among the indirect expenditures, absenteeism, 
reduced productivity, disease related disability, and loss of productivity due to morbidity 
associated with T2DM were the major factors contributing to indirect treatment costs (American 
Diabetes Association, 2013). 
Quality of life is an important parameter that evaluates the health status of a patient (Smith, 
Avis, & Assmann, 1999). The quality of life of a patient is measured by assessing physical and 
social functioning, and the perceived physical and mental well-being of a patient (Sischo & Broder, 
2011). Patients with diabetes often feel challenged by their condition which can affect their day to 
day activity (Joslin Diabetes Center, 2014 ). A study was conducted by Wexler et al. that estimated 
the impact of medical comorbidities, depression, and treatment intensity on quality of life among 
patients with T2DM using the Health Utilities Index-III instrument. The study found that based on 
the scale, median health utility score among patients with T2DM was 0.70 (0 = death to 1.0 = 
perfect health). The study concluded that patients with T2DM have a substantially decreased 
quality of life in association with their symptomatic complications (Wexler et al., 2006). Another 
study by Paschalides et al. examined health-related quality of life in patients with T2DM and found 
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that patients with the T2DM had lower scores for quality of life and it had a significant impact on 
their activities of daily living (Paschalides et al., 2004).  
 
2.4 Antihyperglycemic Medication Adherence 
The American Diabetes Association (ADA) recommends glycosylated hemoglobin (A1C) 
<7% for management of T2DM (Nathan et al., 2009). It recommends the use of antihyperglycemic 
medications along with lifestyle modifications to achieve adequate glycemic control. 
Antihyperglycemic medications are agents that are used to lower blood glucose levels. The ADA 
and the American Association of Clinical Endocrinologists (AACE) recommended the use 
different antihyperglycemic agents used for management of T2DM Table 2.1 (Tsang, 2012). 
Approved medications for T2DM are available in oral and non-oral dosage forms. Medication 
prescribed for T2DM are given as monotherapy and in combination with other antihyperglycemic 
and non-antihyperglycemic agents for management of T2DM. 
 
Table 2.1 Pharmacological agents used for the treatment of Type 2 Diabetes Mellitus 
Drug Class Medications Dosage Form 
Insulins Insulin glargine Injectable 
Biguanides Metformin Oral 
Sulfonylureas Glipizide Oral 
Glinides Nateglinide Oral 
Thiazolidinediones Pioglitazone Oral 
Incretin mimetics Exenatide Injectable 
Amylinomimetics Pramlintide Injectable 
Alphaglycosidase inhibitors Miglitol Oral 
DPP-4 inhibitors Sitagliptin Oral 
SGLT2 Inhibitors Dapagliflozin Oral 
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Maintaining adherence to oral antihyperglycemic medications has been one of the primary 
strategies to achieving long-term glycemic control (Lau DT & DP, 2004). Non-adherent diabetic 
patients have higher glycosylated hemoglobin, higher levels of systolic and diastolic blood 
pressure, as well as higher levels of low-density lipoprotein cholesterol levels (Zhu et al., 2010). 
Among patients with T2DM, non-adherence to antihyperglycemic medications can lead to 
cardiovascular disorders such as coronary artery disease, congestive heart failure, diabetic coma, 
cardiac arrhythmia, thrombotic and embolic cerebrovascular disorders, ischemic heart disease, 
cardiac arrest, and peripheral vascular disease (Cziraky et al., 2015). The literature on T2DM has 
reported that factors such as prescription opioid abuse and overuse, economic factors, dosage 
complexity and external factors (e.g., relationship with a physician, living situation and family 
support) are responsible for non-adherence to antihyperglycemic medication among patients with 
T2DM (Martin, Williams, Haskard, & DiMatteo, 2005; World Health Organization, 2003).  
The majority of adults diagnosed with T2DM use oral antihyperglycemic medications, 
along with lifestyle modification techniques such as a proper diet and exercise, to achieve adequate 
glycemic control (George & Copeland, 2013). Adherence rates for patients with T2DM have 
ranged from 65% to 85% for oral agents (Rubin, 2005). A recent meta-analysis examined overall 
rates of adherence for patients with T2DM who were prescribed oral antihyperglycemic agents 
and found that the pooled medication possesion ratio (MPR) was 75.3%, and the proportion of 
adherent patients was 67.9% (Iglay et al., 2015). Findings from the study suggested that adherence 
rates are suboptimal in patients with T2DM, who were prescribed oral antihyperglycemic 
medications. 
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2.5 Prescription Opioids  
Opioids are chemical compounds that bind to opiate receptors (Rosenblum , Marsch, 
Joseph, & Portenoy, 2008). Opioids are alkaloid derivatives of opium poppy. Prescription opioids 
also include semi-synthetic opiates that are synthesized from naturally occurring opioids (e.g., 
heroin from morphine) (Cambridge Health Alliance, 2015; Filizola & Devi, 2012). Prescription 
opioids are also synthesized from synthetic opioids (e.g., methadone) (Rosenblum, Marsch, 
Joseph, & Portenoy, 2008).  
Prescription opioids are typically used for pain management, cough and diarrhea (Centers 
for Disease Control and Prevention, 2016). Also, prescription opioids are frequently used in the 
management of acute to severe pain following surgery or other traumatic episodes. Moreover, 
prescription opioids are widely used in the treatment of pain related to cancer (Rosenblum et al., 
2008).  
In the US, numerous prescription opioids are approved for various therapeutic conditions. 
These include combination products, or single entity opioid medications as listed in Table 2.2 
(Rosenblum et al., 2008). Promethazine/codeine is a combination antihistamine and opioid which 
is used for treating cough and other upper respiratory symptoms (Drugs.com, 2013). 
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Table 2.2 Opioid based single-entity and combination drugs 
Opioid Based Drugs 
Drug Name Brand Name 
Single-entity opioid medication 
Morphine Avinza®, Kadian®, MS Contina®, MSIR® 
Oxycodone OxyContin® 
Fentanyl Duragesic®, Actiq®, Fentora® 
Hydromorphone Dilaudid® 
Oxymorphone Opana® 
 
Combination based opioid medication 
Hydrocodone and Acetaminophen Vicodin®, Lorcet® 
Hydrocodone and Ibuprofen Vicoprofen® 
Tramadol and Acetaminophen Ultracet® 
Oxycodone and Acetaminophen Percocet® or Percodan® 
aMS - Morphine sulfate 
                                                                                                                                                         
 
2.6 Pain 
Pain is an uncomfortable sensation in body that suggests that something is not functioning 
properly (Woolf, 1989). Pain can be described in many ways based on its type (Closs & Briggs, 
2002). Receptor nerve cells that are in and beneath the skin can sense heat, cold, light, touch, 
pressure, and pain. The human body has thousands of receptor cells that can sense pain. When the 
body undergoes injury, these cells send messages along nerves into the spinal cord and then up to 
the brain. Prescription opioids are analgesics that act by blocking these messages or reduce their 
effect in the central nervous system (US Department of Health & Human Services, 2007). Pain is 
often associated with other symptoms, like nausea, dizziness, or weakness. Unmanaged pain can 
also lead to anger, depression, mood swings or irritability among some patients. Additionally, pain 
can also have a negative impact on a person’s job performance, relationships and independence 
(Institute of Medicine, 2011). 
Pain can be classified as either acute or chronic. Acute pain is often short-lived, and is a 
signal that the body has been injured. Chronic pain is present for long periods of time. Chronic 
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pain is often a result of a disease or a trauma from a past event (e.g., car accident) (Institute of 
Medicine, 2011). Chronic pain can be characterized as pain sensations in the human body over a 
prolonged duration and is defined by the International Association for the Study of Pain as ‘‘pain 
that persists beyond normal tissue healing time, which is assumed to be three months’’ (Roger 
Chou et al., 2009; Elliott, Smith, Penny, Smith, & Chambers, 1999). Chronic pain can be defined 
in various ways, therefore, there is no clear estimate of chronic pain prevalence in the US. A study 
by Clark et al. defined chronic pain as pain being present six months or more in the past year or as 
lasting at least three months (Clark, 2002). Some chronic pain definitions are based on the severity 
of pain (Gureje, Von Korff, Simon, & Gater, 1998). Another study by Elliot et al. has defined 
chronic pain as a painful sensation that acts as a deterrent to regular activities of daily living (Elliott 
et al., 1999). Based on the different definitions, current estimates of chronic pain have ranged from 
12% to 25% (Gaskin & Richard, 2012; Goldberg & McGee, 2011). According to the Institute of 
Medicine, there are more than an estimated 100 million Americans that are suffering from chronic 
pain (Simon, 2012). Furthermore, according to a data from 2010, chronic pain cost the US $635 
billion each year in medical treatment and lost productivity (Simon, 2012). 
The global population is ageing rapidly and the number of elderly people (people over 65 
years of age) will soon exceed that of children under the age of five (World Health Organization, 
2012).  Older people often live with conditions like arthritis, osteoporosis, back and/or cancer pain. 
Chronic pain contributes to disability, decreased mobility, depression, and impaired quality of life 
(Wright M, 2016). Chronic pain can be attributed to multiple factors. It can be caused by an injury, 
such as a back sprain or knee sprain, or it can be due to an illness affecting a patient. Studies have 
shown that pain is a common morbidity among patients who suffer from conditions like fatigue 
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and sleep disturbance (Matthews, 2011). Chronic pain impacts a patient’s limb movements, and it 
leads to reduced flexibility, and decreased strength and stamina (H. y. Cho, Kim, & Kim, 2014).  
 
2.7 Chronic Opioid Use 
Prescription opioids are widely accepted for the treatment of moderate to severe acute pain 
and chronic pain related to active cancer (Rosenblum et al., 2008). Chronic pain can occur in the 
context of various diseases. All chronic pain disorders outside of cancer pain or pain at the end of 
life are known as chronic noncancer pain (CNCP). Prevalent CNCP conditions include back pain, 
osteoarthritis, fibromyalgia, and headache (Roger Chou et al., 2009; van Laar et al., 2012). Patients 
prescribed opioids continue to take prescriptions opioids until they achieve adequate therapeutic 
relief (Wachholtz, Foster, & Cheatle, 2015). In certain scenarios, patients continue to take 
prescription opioids over months for pain management. According to trends and risks of opioid 
use for pain (TROUP) study, chronic or long-term opioid use is defined as receiving opioid therapy 
for greater than 90 days during a calendar year without discontinuation (Sullivan et al., 2008). 
Currently, chronic opioid therapy is recommended in the treatment of pain related to 
different conditions. These conditions include back pain, neuropathic pain, arthritis, depression 
and cough (Kreek, 1988). Opioid prescribing for CNCP has increased in recent years, despite 
limited evidence suppoting long-term effectiveness of prescription opioids over longer durations 
(Berland & Rodgers, 2012; Chou, Turner, Devine, & et al., 2015). One-third of adult Americans 
suffer from chronic pain, and 5% receive opioid treatment; moreover, strong opioids are prescribed 
in up to 9% of all office visits (Berland & Rodgers, 2012). Until the 1990s, physicians prescribed 
opioid treatment to patients following surgery or for cancer-related pain. However, studies during 
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the early 1990’s showed that pain management was inadequate and as a result it led to an increase 
in opioid prescribing for patients with CNCP (Franklin, 2014).  
A review of the literature on prescription opioids suggests that there has been an excessive 
increase in opioid utilization for CNCP. Although some patients benefited from increased 
prescription opioid use for CNCP, there are significant negative effects associated with long-term 
use. The literature on opioid use also suggests that drug tolerance has been seen among patients in 
as little as two weeks of continuous opioid use (Berland & Rodgers, 2012). 
Prescription opioids are also used as antitussive agents. Dextromethorphan is a synthetic 
opioid, which is used as an over-the-counter cough suppressant. Codeine preparations have been 
extensively used for cough management but their clinical efficacy is less certain when prescribed 
over longer durations. For chronic cough management, codeine and hydrocodone preparations 
over a long duration are recommended for cough suppression, though long-term use of prescription 
opioids is associated with major concerns (Dickinson, Morjaria, Wright, & Morice, 2014; Stolz et 
al., 2004).  
 
2.8 Problems Associated with Chronic Opioid Use 
Prescription opioids are the most prescribed medication class for management of chronic 
pain (Rosenblum et al., 2008). Over the past two decades, there has been a tremendous increase in 
the utilization of prescription of opioid medications for chronic pain, despite limited evidence 
showing long-term beneficial effects (Noble et al., 2010; M. D. Sullivan et al., 2008). Some of the 
major issues associated with chronic prescription opioid use are detailed in the following text 
(Clark M, 2012). 
15 
 
Accidental Overdose and Death 
Prescription medications are only safe if taken as directed. An overdose of prescription 
opioid medication can result in death due to opioid overdose (Rosenblum et al., 2008). Combining 
opioids with alcohol, sleep aids or muscle relaxers increases the risk of overdose and death.   
Physical Dependence 
Chronic use of prescription opioids for pain management leads to addiction or dependence. 
Physical dependence leads to drug withdrawal symptoms when a patient stops taking the drug. 
With psychological dependence a patient feels a strong craving for the drug. Alcohol use with 
prescription opioids can also lead to physical dependence. 
Tolerance 
Over time, patients increase their dose of prescription opioid pain medicine to get the same 
amount of relief. This effect of decreased relief over long-term use of prescription opioids is 
refered as tolerance. Tolerance is common with the long-term use of prescription opioid as pain 
receptors become less sensitive to opioids over time (Rosenblum et al., 2008). At some point, 
increasing the dose of medication will not provide adequate pain relief due to the ceiling effects of 
the medication (Rosenblum  et al., 2008). Due to the ceiling effect, patients often require higher 
doses of prescription opioids to receive the adequate relief from pain. Increased doses lead to 
increased risk of side effects and complications. 
Breathing and Heart Problems 
Slower breathing rate is observed among patients with chronic opioid use. It can also stop 
breathing altogether which can lead to death (Walker et al., 2007). Chronic prescription opioid use 
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can cause irregular heart rhythms which can be life threatening at times (Macey, Weimer, 
Grimaldi, Dobscha, & Morasco, 2013).  
Sleep Disorders  
Sleep apnea is a condition identified by long breathing gaps while a patient is sleeping 
(Walker et al., 2007). This leads to low levels of oxygen in the body which can in turn damage 
heart and lungs (Khoo, Kronauer, Strohl, & Slutsky, 1982). Chronic prescription opioid use can 
increase the risk of sleep apnea (Walker et al., 2007).  
Opioid-induced Hyperalgesia 
Chronic prescription opioid-induced hyperalgesia is a condition where opioid medications 
create more pain rather than pain relief (Hay et al., 2009).  
Increase Risk of Fracture 
Prescription opioid use can also affect bone health. Prescription opioids use over a long 
duration can develop osteoporosis. Osteoporosis leads to an increased risk of bone fractures among 
long-term prescription opioid users (Daniell, 2004).  
 
2.9 Chronic Pain and T2DM  
The elderly population often suffers from conditions like arthritis which causes pain to 
different parts of the body. Primarily chronic pain is mainly due to lower back pain and 
osteoarthritis pain (Johannes, Le, Zhou, Johnston, & Dworkin, 2010). Chronic pain is a 
problematic comorbid condition often seen among patients with T2DM. The prevalence of chronic 
pain among those with T2DM ranges from 10% to 42%, and it causes a significant amount of 
disability (Tunks, Crook, & Weir, 2008).  
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2.10 Pharmacologic Management of Chronic Pain 
Chronic pain is characterized by symptoms such as limited mobility, low physical 
functional status, and disturbed sleep patterms. Furthermore, chronic pain can also cause 
depression and anxiety. The management of chronic pain can be addressed by a combination of 
pharmacological agents and also non-pharmacological methods (Ambrose & Golightly, 2015).  
Pharmacological drug classes used to treat chronic pain include NSAIDs, acetaminophen, 
corticosteroids, prescription opioids, antidepressants, and anticonvulsants (American Chronic 
Pain Association, 2015). NSAIDs (e.g., aspirin, ibuprofen) work body by reducing the production 
of prostaglandins (pro-inflammatory chemicals). Prostaglandins are pro-inflammatory chemical 
compounds which are produced when a patient is in the processes of inflammation, pain, and/or 
fever (Pain Community Center, 2015). Tricyclic anti-depressants and serotonin–norepinephrine 
reuptake inhibitors (SNRIs) work by blocking pain messages conducted to the brain, and are also 
believed to stimulate the release of endorphins, which are the body’s natural painkillers (Toft DJ, 
2014). Anticonvulsants help in pain management of chronic pain by slowing down nerve signals 
so that the pain-related nerve signal is not transmitted as efficiently (Toft DJ, 2014). Actions of 
prescription opioids are mainly inhibitory in nature. The presynaptic action of opioids to inhibit 
neurotransmitter release is considered to be their primary mechanism of action. This inhibition of 
neurotransmission results in hyper polarization and a reduction in neuronal excitability, thus 
resulting in decrease of pain (McDonald & Lambert, 2014). 
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2.11 Barriers to Antihyperglycemic Medication Adherence  
Poor antihyperglycemic medication adherence contributes to suboptimal glycemic control, 
which acts as a major barrier to effective diabetes management (Wroth & Pathman, 2006). Low 
adherence to prescribed antihyperglycemic medications accounts for 30% to 50% of treatment 
failures, leading to adverse treatment outcomes which can cause damage to vital organs (Abebe, 
Berhane, & Worku, 2014). Treatment failure is in turn associated with reduced treatment benefits 
and can have a negative financial burden on both patient and society as a whole. Many factors 
affect antihyperglycemic medication adherence among patients who are prescribed prescription 
opioids and antihyperglycemic medications concomitantly. 
Polypharmacy 
Studies have found that patients who are on multiple drugs often have difficulty managing 
their medications, which can lead to adverse drug events (ADEs) and nonadherence to 
medications. A recent report by the Medicare payment advisory commission (MedPAC) suggested 
that ADEs are often associated with opioid use, mainly due to patients taking multiple drugs 
(polypharmacy) and because prescription opioid use itself can lead to many ADEs, including 
unintentional overdoses (The Medicare Payment Advisory Commission, 2015). Therapeutic 
competition occurs when treatment for one medical condition adversely affects another condition. 
Opioid-related therapeutic competition is a side effect of polypharmacy (The Medicare Payment 
Advisory Commission, 2015). One of the most common side effects of prescription opioid is 
constipation. Studies have shown that about 40 percent of patients prescribed prescription opioids 
as an analgesic have experienced constipation and other gastrointestinal effects (Panchal, Müller-
Schwefe, & Wurzelmann, 2007).  
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Prescription Opioid-related Aberrant Drug Behavior  
Use of prescription opioids for CNCP remains controversial (Cowan, Wilson-Barnett, 
Griffiths, & Allan, 2003). There is a dearth of literature on the long-term effectiveness of 
prescription opioids for CNCP. Most of the literature is inconclusive about the long-term efficacy 
of prescription opioids (R. Chou, G. J. Fanciullo, P. G. Fine, J. A. Adler, et al., 2009).  Although 
extensive clinical experience suggests that prescription opioids can improve pain and function in 
some patients, a significant proportion of patients experiences no improvement in functionality. 
Also, opioid use is associated with a variety of potentially serious adverse outcomes which 
includes harms related to drug abuse and diversion (R. Chou, G. J. Fanciullo, P. G. Fine, C. 
Miaskowski, et al., 2009). 
Aberrant drug-related behaviors (ADRBs) refers to drug taking behavior outside clinical 
expectations that may indicate substance misuse, abuse, or addiction. ADRBs can be due to 
factors like undertreated pain or a patient’s misunderstanding of the dosage regimen. According 
to a recent article by the Substance Abuse and Mental Health Services Administration 
(SAMHSA) on chronic opioid use, it stated that at some point in the treatment of chronic pain, 
patients on prescription opioids are likely to fail to adhere to their treatment agreement. Failing 
to adhere to the regimen prescribed due to prescription opioid is indicative of ADRBs among 
those using prescription opioids. Patients with ADRBs often become more interested in their 
prescription opioid medication than in other medications (e.g., antihypertensive) or in any other 
aspect of treatment (e.g., exercise) (Substance Abuse and Mental Health Services Administration, 
2012). 
Patients with ADRBs often demonstrate behavior whereby patients take larger doses of 
prescription opioids than what their prescribed intended. Patients exhibiting ADRBs may also 
20 
 
insist on being prescribed higher doses of prescription opioids. These patients typically resist drug 
screening tests that detect for higher than normal prescription opioid concentration in the body. 
Patients with ADRBs repeatedly lose their opioid medications and seek early refills for 
prescription opioids. Patients with ADBRs are also involved in obtaining opioid medications 
illegally (e.g., from multiple clinicians, street dealers, family members, the Internet, forged 
prescriptions) (Substance Abuse and Mental Health Services Administration, 2012). 
Impulsivity and Prescription Opioid Use 
Impulsivity is defined as choosing a smaller reward that may be obtained immediately over 
a larger reward that may not be obtained immediately (Białaszek, Gaik, McGoun, & Zielonka, 
2015). Logue et al. extended impulsivity theory by including all choices that result in small 
immediate rewards but delayed unpleasant consequences (Logue, 1995). Looking at opioid abuse 
through the lens of impulsivity, it reflects that substance abuse can be best described as a series of 
impulsive choices (Madden, Petry, Badger, & Bickel, 1997). Impulsive choices may predominate 
in prescription opioid users who forego a variety of tangible and social rewards for relatively brief 
but immediately available bouts of drug intoxication or avoidance of transient withdrawal 
symptoms (Madden et al., 1997).  
Use of prescription opioids is associated with increased impulsivity, risky decision making, 
and impaired behavioral control (Madden et al., 1997). This behavior has been explained in the 
model of patient behavior (Madden et al., 1997; Myerson & Green, 1995). It postulates that this 
decrease in value as a function of delay is termed temporal discounting. Temporal discounting 
states that a smaller, more immediate reward may be chosen because the current worth of the 
larger, more delayed reward is discounted; hence, the delayed reward’s current value may be lower 
than that of the more immediate reward (Myerson & Green, 1995). 
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Like other substance abusers, prescription opioid abusers are also impulsive regarding their 
decision making and hence prefer short-term immediate rewards in the form of intoxication and 
forego long-term health rewards otherwise associated with the drug (Madden et al., 1997). 
Socioeconomic Factors and Prescription Opioid Use 
 Prescription drug spending in 2007 was greater than $750 per capita in the U.S., of which 
patients must pay a growing percentage of prescription drug share through medication copayments 
(Kurlander, Kerr, Krein, Heisler, & Piette, 2009). In 2007-2008, nine out of ten older adults used 
prescription medications once a month (Qiuping Gu, 2010). Low-income patients take their 
medications despite paying for copayments; however, one-fifth of those patients do not take 
medications because of cost. Thus, cost-related nonadherence to medications has been associated 
with increased rates of serious adverse events, emergency department visits, hospitalizations, and 
poorer health (Kurlander et al., 2009).  
Kurlander et al. found that of patients who were prescribed prescription opioids and 
antihyperglycemic medications, 9% cut back on medications for both conditions, 13% cut back on 
antihyperglycemic medications alone, and 9% cut back on opioids alone (Kurlander et al., 2009). 
The study found that lower income and higher out-of-pocket medication costs significantly 
increased the odds that diabetic patients would report cost-related non-adherence (Piette, Heisler, 
& Wagner, 2004).  
Need to Treat Symptomatic Conditions 
Chronic pain is a comorbid condition that could be especially troublesome for patients with 
diabetes given its symptomatic manifestation and the accompanying psychological distress and 
physical disability. A study by Krien et al. found that among patients with T2DM and chronic pain, 
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it has been seen that chronic pain affects self-management of T2DM (S. L. Krein, M. Heisler, J. 
D. Piette, F. Makki, & E. A. Kerr, 2005). Patients with T2DM and chronic pain have symptomatic 
and asymptomatic symptoms due to their disorder. Symptomatic conditions include pain whereas 
asymptomatic symptoms include increased glucose level. Taking into account the previous factors 
that can cause non-adherence to antihyperglycemic medications along with a diabetic patients need 
to manage the symptomatic discomfort of pain first, patients may often prefer to take their 
prescription opioids as opposed to their antihyperglycemic medication (S. L. Krein et al., 2005). 
This study was conducted using 2003-2004 MarketScan® Commercial Claims and 
Encounters Database (Commercial). Enrollees in this database were employees, and their 
dependents covered by the employer-based health insurance. Medical claims of patients were 
linked through a unique identifier obtained in the datasets. 
 
2.12 Theory of Rational Addiction 
Several economic and noneconomic approaches to understanding substance abuse 
disorders have focused on how delayed outcomes are discounted in value among patients who 
abuse substances. For example, to explain why an alcoholic chooses to drink over abstinence from 
alcohol, economic theory suggests that the rewards of sustained abstinence and the future costs of 
current drinking are discounted to a high degree. Therefore, subjective value of these costs and 
benefits are minimized relative to the value of the immediate rewards of drinking. The theory of 
rational addiction (Becker & Murphy, 1988), is based on exponential discounting of delayed 
consequences (Becker & Murphy, 1988). According to the theory of rational addiction, substance 
abusers make rational decisions to maximize utility and, in doing so, consider the full cost of using 
drugs when choosing between drug use and abstinence. The total cost of drug use includes a variety 
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of factors including the monetary cost of the drug and the delayed, probabilistic, harmful 
consequences of drug use. Rationally, the benefits of abstinence outweigh the costs associated and 
would seem to favor abstinence (Becker & Murphy, 1988).  
According to the theory, patients using opioids are more impulsive in their decision-
making. A study by Madden and colleagues explained the basis for decision making when patients 
are on opioids (Madden et al., 1997). Among patients on opioids, impulsivity leads to choices that 
result in small immediate rewards but it may have delayed unpleasant consequences. Similarly, 
among chronic opioid users, impulsive choices predominate and thus users forego delayed tangible 
and social rewards. The study found that opioid users had a higher discounting, which is due to 
impulsivity associated with opioid use. Therefore, according to the theory, a patient who wants to 
abuse seeks immediate reward (e.g., intoxication, euphoric experience) over delayed positive 
effects of the event. These findings in the contextof this study, suggest that patients, when 
prescribed antihyperglycemic medications and prescription opioids concomitantly might 
experience impulsivity due to long-term opioid use. This may negatively impact a patient’s 
medication taking behavior. 
 
2.13 Complications of Non-adherence to Antihyperglycemic Medication  
 Diabetes increases the risk for many serious health problems. Maintaining adherence to 
oral antihyperglycemic medications is essential in achieving long-term glycemic control among 
most patients with T2DM. Non-adherence to antihyperglycemic medications can lead to short-
term, and long-term complications among patients with T2DM (EndocrineWeb, 2016). These 
complications develop over years and they are associated with how blood glucose levels can affect 
blood vessels. Elevated levels of blood glucose can damage the blood vessels, both small and large. 
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Long-term complications of T2DM related disorders include retinopathy, kidney disease 
(nephropathy), diabetic neuropathy, and macro vascular problems. Macro vascular complications 
among patients with T2DM can affect large blood vessels, causing plaque to build up over time 
and potentially leading to a heart attack, stroke or vessel blockage in the legs (EndocrineWeb, 
2016).  
 The current literature on T2DM and hospitalization risk suggests that patients who do not 
adhere (i.e., take medication) to at least 80% of their oral antihyperglycemic medications across 
one year are at a higher risk of hospitalization in the following year (Blackburn et al., 2013). It 
also leads to increased healthcare resource utilization. Even with the presence of existing evidence 
regarding antihyperglycemic medications and subsequent hospitalization risk, there is a lack of 
literature to examining whether concomitant prescribing of prescription opioids and 
antihyperglycemic medications can negatively impact antihyperglycemic medication adherence 
and thus lead to subsequent diabetes related hospitalizations. 
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CHAPTER THREE: MANUSCRIPT 1 
IMPACT OF LONG-TERM OPIOID MEDICATION USE ON ORAL 
ANTIHYPERGLYCEMIC MEDICATION ADHERENCE AMONG PATIENTS WITH TYPE 
2 DIABETES MELLITUS 
 
3.1 Abstract 
Introduction: Adherence to antihyperglycemic medication is imperitive to accomplish adequate 
glycemic control among patients with T2DM. Chronic and neuropathic pain causes hindrance 
to achieving the glycemic goal among patients with T2DM. This analysis compares adherence 
to antihyperglycemic medications among patients with T2DM, who are concomitantly 
prescribed opioids. 
Methods: This retrospective cohort study utilized the 2003-2004 US MarketScan® (Truven 
Health Analytics, Ann Arbor, MI, USA) Commercial health insurance claims data. Adults 
aged 18 years with T2DM who received prescription opioids were included. Adherence to 
antihyperglycemic medications was calculated among long-term (≥ 90 days) opioid users and 
short-term (< 90 days) opioid users who were prescription opioid naïve in the baseline period. 
Adherence was measured using the proportion of days covered (PDC), with PDC of ≥ 0.80 
considered adherent. Multivariable logistic regression was used to predict antihyperglycemic 
medication adherence between the cohorts, while controlling for baseline differences. 
Results: There were 22,212 patients with T2DM, of which 7,294 (32.8%) were long-term opioid 
users, and 14,918 (67.2%) were short-term opioid users. During the 6-month follow-up, long-term 
opioid users were 1.37 times more likely to be adherent to their antihyperglycemic medication 
therapy as compared to short-term opioid users (OR = 1.37, 95% CI = 1.28-1.47). 
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Conclusion: Adherence to antihyperglycemic medication increased after patients initiated 
prescription opioids. Patients with T2DM who were prescribed long-term prescription opioids 
as compared to short-term prescription opioids were more adherent to their antihyperglycemic 
medications.  
 
3.2 Background 
Opioid analgesics are widely accepted as one of the most effective medication class for the 
management of pain. Prescription opioids were initially prescribed for pain management among 
patient’s post-surgery and among patients with cancer. Opioids are now considered one of the most 
potent and efficient drugs for the management of non-cancerous acute and chronic pain, treating 
both moderate to severe conditions (Savage, Kirsh, & Passik, 2008). The use of opioids for pain 
management has increased significantly in the US over the last two decades (Laxmaiah 
Manchikanti, 2012). The amount of prescription opioids prescribed for pain management has 
increased significantly in the past 20 years for chronic pain management despite limited evidence 
demonstrating the long-term beneficial effects (Volkow & McLellan, 2016). In the US, the number 
of prescriptions for opioids (e.g., hydrocodone) escalated from 76 million in 1991 to approximately 
207 million in 2013 (National Institute of Drug Abuse, 2014). The US has become the biggest 
consumer globally of opioids based medications. Furthermore, the US accounts for almost 100 
percent of hydrocodone and 81 percent for oxycodone prescribed globally in the year 2013 
(National Institute of Drug Abuse, 2014).  
Greater availability and increased prescribing of prescription opioids is associated with 
increases in abuse related to these medications. For example, the number of emergency department 
(ED) visits involving the non-medical use of opioid analgesics doubled from 144,600 in 2004 to 
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305,900 in 2008 (National Institute of Drug Abuse, 2014). Prescription opioid-related overdose 
deaths have more than tripled during the last 20 years (National Institute of Drug Abuse, 2014). In 
2010, 16,651 people died because of prescription opioid-related overdose in the US (Behavioral 
Health Coordinating Committee - Prescription Drug Abuse Subcommittee, 2013). The mechanism 
of action of prescription opioids is similar to that of heroin, as they both impact the human brain 
by generating a surge of euphoria upon usage. The onset and intensity of euphoric experience 
varies by the route of administration and formulation. However, all prescription opioids when not 
taken as prescribed by patients can cause physical dependence, abuse, and addiction. (National 
Institute of Drug Abuse, 2014). 
 Opioids for Chronic Pain 
Chronic pain affects approximately one-third (100 million) of US adults, and five percent 
of these patients suffering with chronic pain receive opioid treatment for pain management 
(National Institute of Drug Abuse, 2014). Use of prescription opioids has increased significantly, 
as one study suggests that the use of strong opioids (e.g, oxycodone) is seen in up to nine percent 
of all office visits (Berland & Rodgers, 2012). A significant number of patients with chronic pain 
are prescribed opioids over long durations. Currently, most literature does not support the use of 
long-term opioids for chronic pain management (Chou et al., 2015). Studies report that long-term 
opioid use is associated with diversion and deaths due to the non-medical use of prescription 
opioids (Compton, Jones, & Baldwin, 2016). Pain is a comorbid condition that affects 40% of 
patients with T2DM (Rebecca L. Sudore et al., 2012). For most of these people, the pain is chronic, 
defined as pain persisting for more than 90 days (Valkanoff, Kline-Simon, Sterling, Campbell, & 
Von Korff, 2012). Among diabetics, pain can be neuropathic pain from diabetic peripheral 
neuropathy or non-neuropathic pain which includes musculoskeletal conditions, such as 
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osteoarthritis, shoulder disorders, and lower back pain (Averyt, 2012). Regardless of the cause, 
previous literature suggests that chronic pain can affect diabetes self-management. 
Non-medical Use of Prescription Opioids 
The non-medical use of prescription opioids is a significant problem in the US. It is 
characterized by using opioid analgesics more than they were prescribed, or obtaining them 
without a prescription from sources other than pharmacies. Non-medical use of prescription 
opioids is typical when patients want to experience euphoric sensations (Compton et al., 2016). In 
2014, non-medical use of prescription opioids was reported by 10.3 million patients (Compton et 
al., 2016). ED visits due to the non-medical use of prescription opioids increased 153% between 
2004 and 2011. In the last decade, the rates of death due to non-medical use of opioids have rose 
from 1.5 to 5.9 per 100,000 people (Compton et al., 2016). According to a recent article by the 
Substance Abuse and Mental Health Services Administration (SAMHSA) on chronic opioid use, 
it stated that at some point in the treatment of chronic pain, patients are likely to fail to adhere to 
their treatment agreement. Patients using opioids over longer durations demonstrate aberrant drug-
related behaviors (ADRBs). ADRBs refers to drug taking behaviors which demonstrate substance 
misuse, abuse, or addiction. Patients with ADRBs are often more interested in prescription opioids 
than in their other medication treatment(s) (Substance Abuse and Mental Health Services 
Administration, 2012). 
Antihyperglycemic Medication Adherence and Barriers to Adherence 
Adherence to antihyperglycemic medications is a primary factor required to achieve 
adequate glycemic control among patients with T2DM. Non-adherence to antihyperglycemic 
medication is attributed to 30% to 50% of the patients who don’t achieve adequate glycemic 
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control from their prescribed antihyperglycemic, which leads to poorer health outcomes (Abebe et 
al., 2014). Several factors that can affect adherence to oral antihyperglycemic medications have 
been identified in the literature. These factors include younger age, female gender, patients living 
in the Southern region of the US, polypharmacy, socioeconomics factors, and high cost-sharing is 
associated with lower adherence to oral antihyperglycemic medications. With ADRBs associated 
with long-term users of prescription opioids, it can potentially affect adherence to diabetic 
medication when taken concomitantly. 
  To our knowledge, no previous study has examined the impact of opioid use on 
antihyperglycemic medication adherence when prescribed concomitantly. Considering the 
ADRBs associated with long-term opioid use, it is imperative to study the effect of long-term 
prescription opioid use when prescribed concomitantly with antihyperglycemic medications. This 
study compared the adherence of oral antihyperglycemic medication among patients with T2DM 
who are prescribed long-term (≥90 days) and short-term (less than 90 days) of prescription opioids.  
 
3.3 Methods 
Data Source 
Administrative claims data from the Truven Health MarketScan® (Truven Health 
Analytics, Ann Arbor, MI, USA) was used to address the objective of this study. MarketScan® 
data is collected from employers, health plans, and state Medicaid agencies. MarketScan® consists 
of three core claims databases, a hospital discharge database as well as several linked databases, 
data sets, and files that link claims data to other patient and employee data at the patient level. 
This study was conducted using 2003-2004 MarketScan® Commercial Claims and 
Encounters Database (Commercial). Enrollees in this database were employees, and their 
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dependents covered by the employer-based health insurance. Medical claims of patients were 
linked through a unique identifier obtained in the datasets. 
3.4 Sample and Study Design 
Patients aged 18 years and older were included in this study. Patients were required to be 
continuously enrolled for the study duration and have at least one non-diagnostic medical claim 
with a T2DM diagnosis ([ICD-9-CM] 250.x0, 250.x2) in the baseline and follow-up period. Also, 
these patients were required to have at least one outpatient pharmacy claim with a National Drug 
Code (NDC) for an antihyperglycemic medication (e.g., sulfonylureas, biguanide). Patients with 
Type 1 diabetes mellitus, diabetes in pregnancy and disease conditions where opioids are 
prescribed for non-diabetes related pain management were also excluded (e.g., cancer, 
fibromyalgia, falls and fractures, surgeries).  
According the to the study design in Figure 3.1, patients with T2DM and an 
antihyperglycemic medication claim and no prescription opioid claim were identified in the first 
six months of study. Of these, patients with an antihyperglycemic medication claim and 
prescription opioid claim were selected in the patient’s accrual window. Prescription opioid 
persistence was measured over 90 days among patients from their first claim of prescription opioid, 
in order to classify them as long-term opioid users (≥ 90 days) and short-term opioid users (< 90 
days). Subsequent adherence to antihyperglycemic medication was measured over six months 
from the day the patient was classified as long-term or short-term user of prescription opioids.  
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Figure 3.1 Study design  
 
 
3.5 Statistical Analysis  
For descriptive analyses, frequencies were measured for all study variables. A pairwise t-
test was conducted to estimate the difference in antihyperglycemic medication adherence before 
and after opioid use for the same inidividual. A multivariable logistic regression model was used 
to compare the odds of being adherent to antihyperglycemic medication. Logistic models 
controlled for age, gender, region, plan type, capitated payment, baseline diabetes adherence, 
elixhauser comorbidity score for non-diabetes related severity and adapted diabetes complications 
severity index (aDCSI) score for diabetes-related severity. A sensitivity analysis was conducted 
by defining the long-term opioid use as greater than 60 days, with a maximum discontinuation of 
5 days. A second sensitivity analysis was conducted among patients who were adherent to 
antihyperglycemic medication in the baseline period (PDC ≥ 0.80). An a priori alpha level of 0.05 
was used to determine statistical significance. Analyses were conducted with SAS version 9.3 
(SAS Institute Inc. Cary, NC, USA). 
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3.6 Patient Selection 
As seen in Figure 3.3, for the analysis, 923,902 patients  were identified with T2DM. After 
meeting all tcriteria, there were 22,212 patients in the selection window; 7,294 (32.8%) were long-
term opioid users, and 14,918 (67.2%) were short-term opioid users. 
Figure 3.2 Patient attrition flow chart 
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3.7 Results 
Descriptive Statistics 
According to Table 3.1, mean age for patients with long-term opioid use was 55.82±6.52, 
years and mean age for patients with short-term opioid usage was 53.13±7.87. The majority of  
long-term opioid users were male (53.51%) whereas most of the patients using short-term opioids 
were female (52.13%). Mean non-diabetes severity reported through the elixhauser index was 
0.12±1.10 for long-term opioid users, and was 0.13±1.06 for short-term opioid users. Mean 
diabetes severity was 0.80±0.32 for long-term opioid users and 0.78±0.37 for short-term opioid 
users. 
 
 
 
 
 
 
 
 
 
 
 
34 
 
Table 3.1 Frequency and distribution of patient demographic charecteritics 
 Long-term opioid users Short-term opioid users P-Value              
 n = 7,012 n = 13,492               
 Mean SD Mean SD               
Age, years  55.82 6.52 53.13 7.87 0.001              
Clinical characteristics               
aElixhauser Indexa 0.12 1.10 0.13 1.06 0.85              
aDCSIb  0.80 0.32 0.78 0.37 0.56              
               
 N % N %               
Gender               
Male 3,752 53.51 6,459 47.87 <0.001              
Female 3,260 46.49 7,033 52.13 <0.001              
Region                
Northeast 550 7.84 599 4.44 <0.001              
North Central 2,501 35.67 4,018 29.78 <0.001              
South 2,394 34.14 6,488 48.09 <0.001              
West 1,567 21.62 2,387 17.10 <0.001              
Insurance plan type               
Basic and comprehensive 
plans 
1,801 25.68 2,347 17.40 <0.001 
             
CDHP and HDHPc 2,464 35.14 4,481 33.21 <0.001              
Capitated plan 2,724 38.85 6,627 49.12 <0.001              
Non-capitated plan 23 0.33 37 0.27 <0.001              
Presence of Capitated payment                
Capitated 1,112 15.86 1,373 10.18 <0.001              
Non-capitated 5,899 84.14 12,108 89.82 <0.001              
a Adapted Elixhauser Index 
b Adapted diabetes severity comorbidity index 
c Consumer-directed health plan/high-deductible health plan 
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Opioid Persistence 
Patients were defined as a long-term or short-term users of prescription opioids based on 
their persistence to opioid medications. As seen in Table 3.2, 32.38% of opioid users in the cohort 
were long-term users and 67.16% were short-term users. 
Table 3.2 Opioid persistence for patients in the follow-up period 
Numbers of patients (Total = 22,212) 
Duration N (%) 
Long-term opioid use (≥90 days) 7,294 (32.84) 
Short-term opioid use (< 90 day) 14,918 (67.16) 
 
Adherence to Antihyperglycemic Medication 
Mean adherence for patients in the baseline period (n= 108,043) was 0.68±0.25. As seen 
in Table 3.3, of these patients who had long-term opioid use (n = 7,012) their baseline 6-month 
antihyperglycemic adherence was 0.76±0.22, and their 6-month antihyperglycemic adherence in 
the follow-up period was 0.84±0.20. For patients in the short-term opioid user group (n = 13,492), 
their baseline 6-month antihyperglycemic adherence was 0.67±0.25, and their 6-month 
antihyperglycemic adherence in the follow-up period was 0.76±0.24. 
Table 3.3 Antihyperglycemic adherence in the baseline and follow-up period 
Opioid therapy duration Baseline Duration PDCa Follow-up Duration PDC 
Long-term opioid use 0.76±0.22 0.84±0.20 
Short-term opioid use 0.67±0.25 0.76±0.24 
aPDC – Proportion of days covered 
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Pairwise t-test results (Table 3.4) shows the difference in the adherence scores for patients 
in the baseline and follow-up. Findings demostrated that there was a significant difference between 
baseline and follow-up adherence scores. 
Table 3.4 Pairwise t-test to compare antihyperglycemic medication adherence at baseline and 
follow-up  
Opioid therapy duration Total number of patients DF t-statistic P-Value 
Long-term opioid users 
(≥ 90) 7,012 7,011 -23.52 <0.0001 
Short-term opioid users 
(< 90) 13,492 13,491 -37.56 <0.0001 
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Multivariable Logistic Regression Analysis 
Table 3.5 presents adherence results among users who were concomitantly prescribed long-
term or short-term prescription opioid therapy. In the adjusted logistic regression model, patients 
who were long-term opioid users were more adherent to their antihyperglycemic medication than 
short-term opioid users. During the 6-month follow-up, long-term opioid users (OR =1.37, 95% 
CI = 1.28-1.47) were 1.37 times more adherent to their antihyperglycemic medication therapy as 
compared to short-term opioid users. Females (OR = 0.89, 95% CI = 0.84-0.95) were less adherent 
to antihyperglycemic medication adherence as compared to males. Patients in the age group of 31 
to 45 years (OR = 1.52, 95% CI = 1.11-2.10), 46-60 years (OR = 2.59, 95% CI = 1.90-3.54), and 
patients above 60 years (OR = 3.23, 95% CI = 2.36-4.34) were more adherent to antihyperglycemic 
medications as compared to patients in the age group of 18 to 30 years. 
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Table 3.5 Multivariable logistic regression to estimate predictors of antihyperglycemic 
medication adherence 
Parameter Odds Ratio 
95% Wald’s 
Confidence Limits P Value 
Opioid Use (Ref = Short-term opioid use) 
Long-term opioid use 1.37 1.28 1.47 <.01 
Gender (Ref = Male)  
Female 0.89 0.84 0.95 0.02  
Region (Ref = Northeast)  
North central 1.15 0.99 1.32 0.06  
South 0.98 0.85 1.12 0.75  
West 0.90 0.76 1.07 0.23  
Age Category (Ref = 18 – 30 years)  
31- 45 years 1.52 1.11 2.10 0.01  
46 - 60 years 2.59 1.90 3.54 <.01  
Greater than 60 years 3.23 2.36 4.34 <.01  
Health Plan Type (Ref = Basic and comprehensive plans)  
Non capitated plan 0.81 0.74 0.90 <.01  
Capitated plans 0.88 0.80 0.96 0.01  
CDHP and HDHPa 0.87 0.50 1.50 0.61  
Capitated Service (Ref = No)  
Yes 1.23 1.05 1.43 0.01  
Non-diabetes Severity index  
aElixhauser indexb 0.97 0.95 1.00 0.05  
Diabetes Severity Index  
aDCSIc 0.94 0.86 1.02 0.15  
Baseline Antihyperglycemic Adherence  
Baseline antihyperglycemic adherence 15.08 13.26 17.16 <.01  
a Consumer-Driven Health Plan/High Deductible Health plan 
b Adapted Elixhauser Index       
cAdapted diabetes severity comorbidity index 
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3.8 Discussion 
Use of long-term opioids has been under scrutiny because of limited evidence 
demonstrating the effectiveness of opioids for chronic pain or other conditions. The results of this 
study suggest an increase in antihyperglycemic medication adherence among patients with T2DM 
in both short-term and long-term opioid use. The results were inconsistent with findings from the 
SAMHSA long-term opioid use guideline which suggests that concomitant use can affect the 
adherence to other medications. 
The results from the multivariable analysis suggested that long-term users of prescription 
opioids were more adherent to their antihyperglycemic medication as compared to short-term 
opioid users. Although, the results were not consistent with SAMHSA opioid use guideline, the 
results were in accordance with the existing literature which suggests that long-term opioid users 
tend to better manage their pain, which in turn helps them manage their T2DM more effectively. 
In a study by Guerriero et al., patients with long-term opioid use managed their pain other 
conditions better than patients not receiving opioid therapy. Similar findings were reported by 
Krien et al., in that better management of chronic pain (i.e., taking pain medication) seemed to 
improve diabetes self-management. However, long-term use of prescription opioids is associated 
with serious health consequences and can lead to addiction, dependence or aberrant drug taking 
behaviors. 
A few limitations related to this study should be discussed. Administrative claims data is 
primarily collected for billing and reimbursement purposes by health care plans and not necessarily 
for research. Data entry errors are common among these administrative databases. As this was a 
retrospective observational analysis, causal inferences should not be drawn. The calculation for 
adherence was based on days’ supply and service dates, but this does not confirm whether the 
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patient ingested the medication. Also, with prescription opioids, there are many cash payments 
(i.e., non-insurance), which cannot be calculated using this database. Further, the years of available 
data was somewhat limiting. Therefore, examining medication adherence over a longer follow-up 
period was not possible. The database used for this study is not recent, thus limiting any 
medications approved at a later date. As this data is limited to individuals on commercial health 
plans, findings from the study may not be generalizable to the entire US population. 
 
3.9 Conclusion 
Patients using long-term opioid therapy were more adherent to their antihyperglycemic 
medication as compared to patients using short-term opioid therapy when prescribed 
concomitantly with antihyperglycemic medications. Sensitivity analyses also produced similar 
findings. Results from this study did not demonstrate any decrease in antihyperglycemic 
medication adherence after prescription opioid use, but explained that perhaps with better pain 
management, patients may have better health outcomes among patients with T2DM. Negative 
consequences of long-term opioid use cannot be ruled out and future studies with a longer follow- 
up period should be conducted to investigate whether long-term prescription opioid use negatively 
impacts antihyperglycemic medication adherence.  
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CHAPTER FOUR: MANUSCRIPT 2 
IMPACT OF LONG-TERM OPIOID MEDICATION USE ON SUBSEQUENT TYPE 2 
DIABETES MELLITUS RELATED HOSPITALIZATIONS 
4.1 Abstract 
Introduction: Patients’ adherence to antihyperglycemic medication is an essential component in 
achieving adequate glycemic control. Non-adherence to antihyperglycemic medication can lead to 
macro vascular and micro vascular complication among patients with type 2 diabetes mellitus 
(T2DM). According to the SAMSHA opioid use guideline, prescription opioid use can potentially 
have a negative impact on chronic asymptomatic medication therapy. Thus, antihyperglycemic 
medication adherence may decrease and subsequently lead to T2DM related hospitalizations. 
Methods: T h i s  study was a retrospective cohort analysis that utilized 2003-2004 US 
MarketScan® (Truven Health Analytics, Ann Arbor, MI, USA) commercial health 
insurance claims databases. Adults aged 18 years and older with T2DM who were 
prescribed prescription opioids were included. Adherence to antihyperglycemic medications 
was calculated among long-term (≥ 90 days) opioid users and short-term (< 90 days) opioid 
users. Patients with prior hospitalization before the index date were excluded. Adherence was 
measured using proportion of days covered (PDC), with PDC ≥0.80 considered adherent. Risk 
of subsequent T2DM related hospitalizations was estimated using a cox proportional hazard 
regression model by comparing long-term and short-term users of prescription opioids. 
Results: There were 22,212 patients in the study, out of which 7,462 (33.66%) were long-term 
opioid users and 14,736 (66.34%) were short-term opioid users. During the 6-month follow-up, 
risk of T2DM related hospitalization was lower among long-term opioid users in 150 days or less 
during follow-up (HR = 0.73, 95% CI = 0.69-0.78) as compared to short-term prescription opioid 
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users. Whereas risk of T2DM related hospitalization was more among patients with long-term 
prescription opioid use greater than 150 days during the follow-up (HR = 1.25, 95% CI = 0.69- 
2.28) as compared to short-term opioid users. Follow up antihyperglycemic adherence (HR = 1.44, 
95% CI = 1.25-1.64) was a significant predictor of T2DM related hospitalization when assessed 
as a mediator. 
Conclusion: Patients who were concomitantly prescribed long-term prescription opioids and 
antihyperglycemic medications were at a lower risk of T2DM related hospitalizations as compared 
to patients who were prescribed short-term prescription opioids. Use of prescription opioids over 
a longer duration did not negatively impact T2DM related hospitalizations when prescribed 
concomitantly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
4.2 Background 
Diabetes Mellitus (DM) is a chronic, progressive disorder characterized by hyperglycemia, 
which affects 9.3% of the total population of the U.S (W. C. Cho et al., 2006; Control & 
Prevention, 2014b). Approximately 1.4 million cases of DM are diagnosed in the US every year 
(Control & Prevention, 2014a). Of patients diagnosed with DM, 90% - 95% patients suffer from 
T2DM (Richardson & Pollack, 2005). T2DM management is also associated with a high economic 
burden. Furthermore, T2DM is associated with a significant decline in quality of life (Dall et al., 
2010). A study by Condliffe et al. reported that in the year 2007, annual direct costs for T2DM 
management was $11,917 per person (Condliffe, Link, Parasuraman, & Pollack, 2013). Due to the 
progressive nature of the disorder, T2DM when not adequately treated can lead to macro vascular 
and micro vascular complications such neuropathy and nephropathy (Cade, 2008).  
The progression towards macro vascular and micro vascular complications due to 
uncontrolled diabetes can prevented by maintaining adequate glycemic levels by using appropriate 
pharmacotherapy for T2DM management. Maintaining adherence to antihyperglycemic 
medications is thus a key factor in the proper management of T2DM. Non-adherence to 
antihyperglycemic medications leads to higher glycosylated hemoglobin, higher blood pressure 
and higher LDL cholesterol levels, all of which lead to micro vascular and macro vascular 
complications, which result in rapid progression of disease and an increased risk of cardiovascular 
disorders (Wabe, Angamo, & Hussein, 2011). However, despite these facts, adherence to oral 
antihyperglycemic medications has been found to be suboptimal among patients with T2DM. A 
study by Kirkman et al. reviewed the literature on antihyperglycemic medication adherence rates 
and found that adherence rates for oral antihyperglycemic agents ranged from 36% to 93% 
(Kirkman et al., 2015). Factors negatively affecting antihyperglycemic medication adherence lead 
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to poor T2DM management. Subpar antihyperglycemic medication adherence eventually results 
in T2DM related complications and poor patient outcomes characterized by increased 
hospitalizations related to T2DM (Lau & Nau, 2004).  
Pain is an uncomfortable sensation in the body that suggests something underlying the pain 
is amiss. Chronic pain is often a comorbid condition that is troublesome for patients with T2DM 
given its associated physical disability and mental distress. Patients with T2DM often suffer from 
pain due to other comorbidities like arthritis and low back pain. A study by Sudore et al. reported 
that among patients with T2DM, 41.8% and 39.7% reported suffering from acute and chronic pain 
respectively (R. L. Sudore et al., 2012). Non-chronic pain among patients with T2DM is often 
caused by diabetic neuropathy. The presence of chronic pain among patients T2DM can influence 
patients T2DM care management (Sarah L. Krein, Michele Heisler, John D. Piette, Fatima Makki, 
& Eve A. Kerr, 2005). 
The use of pharmacotherapy to alleviate pain is an important component of chronic pain 
management. Pharmacotherapy based management for chronic pain includes NSAIDs, opioid 
analgesics, antidepressants and anticonvulsants (American Diabetes Association, 2015). 
Prescription opioids have been regarded as the most effective medication for management of pain. 
Prescription opioid use in the management of chronic pain is considered a standard of care in the 
US. A dramatic increase in use of prescription opioids for chronic pain management has also 
occurred over the last two decades (Laxmaiah Manchikanti, 2012). The existing literature on long-
term opioid use does not support the use of prescription opioids over long-term for chronic pain 
management due to concerns of negative consequences (e.g., abuse) (Kalso, Edwards, Moore, & 
McQuay, 2004). In addition, there is growing body evidence indicating increased rates of the 
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harmful effects associated with high prevalence of prescription opioid use, including accidental 
overdose, abuse, addiction, and diversion (Katz et al., 2013). 
The Substance Abuse and Mental Health Services Administration (SAMHSA) guideline 
on chronic opioid use states that patients with long-term opioid use are more likely to demonstrate 
aberrant drug-related behaviors (ADRBs), which may negatively affect their adherence to other 
prescribed treatments (Substance Abuse and Mental Health Services Administration, 2012). 
Patients with ADRBs often demonstrate behaviors that are indicative of substance misuse, overuse, 
abuse, or addiction. Patients with ADRBs are also more likely to be interested in their prescription 
opioids than in their other chronic asymptomatic medications (e.g., antihypertensive) when 
prescribed concomitantly (Substance Abuse and Mental Health Services Administration, 2012). 
Patients with T2DM often suffer with chronic pain or cough which are often treated with 
prescription opioids. According to SAMHSA guidelines on opioids, the continuous use of 
prescription opioids over a long duration of time can lead to ADRBs, which can affect 
antihyperglycemic medication adherence among patients with T2DM patients. 
Non-adherence to antihyperglycemic medication is associated with an increased risk of 
hospitalizations due to diabetes and cardiovascular complications (Sokol, McGuigan, Verbrugge, 
& Epstein, 2005). At least one study has shown that patients with adherence rates greater than 80% 
were significantly less likely to be hospitalized as compared with patients who had adherence less 
than 80% (Brown & Bussell, 2011). Even with the presence of existing evidence regarding 
antihyperglycemic medication adherence and subsequent hospitalization risk, there is limited 
research which has explored diabetes related outcomes (e.g., hospitalizations) when patients are 
prescribed prescription opioids (Lau & Nau, 2004). Therefore, the objective of this study was to 
evaluate the relationship between oral antihyperglycemic medication adherence and subsequent 
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risk of T2DM related hospitalization among patients, who were prescribed long-term prescription 
opioids as compared to patients who were prescribed short-term prescription opioids.  
4.3 Methods 
Data Source 
Administrative claims data from the Truven Health MarketScan® (Truven Health 
Analytics, Ann Arbor, MI, USA) was used to address the study objective. MarketScan® data is 
collected from employers, health plans, and state Medicaid agencies. This study was conducted 
using 2003-2004 MarketScan® Commercial Claims and Encounters Database. The database 
contains information about enrollees and their dependents, which were covered through  employer 
sponsered healthpans.  
 
4.4 Sample and Study Design 
According to Figure 4.1, a retrospective study was designed to analyze the association 
between concomitant antihyperglycemic and prescription opioid use and its effect on T2DM 
related hospitalization risk while controlling for antihyperglycemic medication adherence. Patients 
aged 18 and older were included in the study cohort. Patients were required to be continuously 
enrolled for the study duration and have at least one T2DM diagnosis claim ([ICD-9-CM] 250.x0, 
250.x2) in the baseline and follow-up duration. Also, these patients needed to have at least one 
outpatient pharmacy claim with a National Drug Code (NDC) for an antihyperglycemic 
medication (e.g., sulfonylureas, biguanide). Patients with any prescription opioid history or 
diabetes related hospitalizations were excluded. Patients identified in the selection window were 
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classified into long-term users of prescription opioids (≥ 90 days) and short-term users of 
prescription opioids (< 90 days) based on their 90-day persistence to opioid therapy. Once 
classified as long-term and short-term users of prescription opioids, risk of diabetes related 
hospitalization were compared taking into account their follow-up antihyperglycemic medication 
adherence. Antihyperglycemic adherence was measured over 6 months from the day the patient 
was classified as a long-term or short-term user of prescription opioids.  
 
 
Figure 4.1 Study design to estimate T2DM related hospitalizations among patients prescribed 
prescription opioids 
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Outcome Variable 
The objective of this study was to measure T2DM related hospitalization risk among 
patients with T2DM who were prescribed concomitantly an antihyperglycemic medication and 
prescription opioid. For each patient, the study identified T2DM related hospital admission during 
the follow-up period based on Table 4.1.  
 
Table 4.1 ICD 9 – CM codes for T2DM related hospitalizations 
Type of diabetes-related hospitalizations ICD-9 codes 
Uncontrolled T2DM 250.02 
Septicemia or bacteremia 038.xx, 790.7 
Pneumonia 480-6 
Kidney infections, cystitis, urinary tract 
infection 590, 595, 599.0x 
Cellulitis 680-682, 686 
Electrolyte imbalance 276.xx 
Diabetes retinopathy 250.5x, 361.xx, 362.0x, 362.1, 362.8x, 379.23, 369.xx 
Diabetic nephropathy 250.4x, 585.xx, 593.9 
Diabetic neuropathy 250.6x, 356.9, 357.2x 
Ischemic heart disease 410-414, 
Stroke 433-434 
Diabetes peripheral circulatory disorders 250.7x, 440.2x, 707.1x, 785.4x 
ICD 9 -CM - The International Classification of Diseases, Ninth Revision, Clinical Modification  
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Independent Variable 
The primary independent variable of interest was duration of opioid therapy. Demographic 
and clinical variables were measured and controlled for potential confounding in the multivariable 
models. Demographic variables included were gender, age, geographic region, presence of 
capitated services, and insurance plan type. Non-diabetes related clinical characteristics were 
measured during the baseline period, and it was captured using the adapted Elixhauser comorbidity 
index, and diabetes-related clinical characteristics were measured using the adapted diabetes 
complications severity index (aDCSI). The adapted Elixhauser comorbidity index is used to 
calculate and predict in-hospital mortality. Whereas, the aDCSI is a DM specific severity scale 
used in predicting mortality and hospitalizations. The aDCSI is a modified version of the diabetes 
complications severity index, which is calculated with lab data (e.g., HbA1c). The aDCSI 
estimates diabetes severity using claims data are similar to DCSI diabetes severity estimates. The 
influence of antihyperglycemic adherence as a mediator on the hospitalization risk was evaluated 
by using two separate regression models, one with antihyperglycemic medication and the other 
without antihyperglycemic medication adherence being considered. Antihyperglycemic 
medication adherence was measured as the proportion of days covered (PDC), calculated by taking 
the number of days a patient had the T2DM medication while taking opioid medications on hand 
during the 180 days’ follow-up divided by the follow-up time. Patients with PDC ≥ .80 were 
considered adherent to their prescribed antihyperglycemic medication. 
PDC = 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑑𝑑𝑇𝑇𝑑𝑑𝑑𝑑 𝑇𝑇𝑎𝑎𝑇𝑇𝑎𝑎ℎ𝑑𝑑𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑦𝑇𝑇𝑑𝑑𝑦𝑦𝑦𝑦𝑦𝑦𝑎𝑎𝑦𝑦 𝑦𝑦𝑦𝑦𝑑𝑑𝑎𝑎𝑦𝑦𝑇𝑇𝑇𝑇𝑎𝑎𝑇𝑇𝑎𝑎 𝑇𝑇𝑎𝑎𝑇𝑇𝑎𝑎𝑇𝑇𝑇𝑇𝑎𝑎𝑇𝑇𝑦𝑦
𝐷𝐷𝑇𝑇𝑑𝑑𝑑𝑑 𝑎𝑎𝑎𝑎 𝑓𝑓𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑓𝑓−𝑢𝑢𝑦𝑦 𝑦𝑦𝑦𝑦𝑦𝑦𝑎𝑎𝑇𝑇𝑑𝑑  
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4.5 Statistical Analysis 
             For descriptive statistics, frequencies were measured for all study variables in both long-
term and short-term opioid users. Cox proportional hazard regression models were fit to compare 
the subsequent T2DM related hospitalization risk among patients prescribed long-term 
prescription opioids versus patients prescribed short-term prescription opioids concomitantly 
along with their antihyperglycemic medications. Models controlled for the following variables: 
age, sex, region, insurance plan type, capitated payment and baseline diabetes adherence. 
Additionally, non-diabetes severity was controlled for by the adapted Elixhauser comorbidity 
index. Diabetes severity was controlled using the adapted diabetes complications severity index 
(aDCSI) score. A sensitivity analysis was conducted by defining the long-term prescription opioid 
use as greater than 60 days, with a maximum discontinuation of 5 days. Another sensitivity 
analysis was conducted among patients who were adherent to antihyperglycemic medication in the 
baseline duration (PDC ≥ 0.80). An apriori alpha of 0.05 was used to determine statistical 
significance. Analyses were conducted with SAS version 9.3 (SAS Institute Inc. Cary, NC, USA). 
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4.6 Patient Attrition Flowchart 
 
Figure 4.2 Patient attrition flow chart 
 
 
LTO - Long term opioid  
STO - Short term opioid 
PDC - Proportion of days covered  
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4.7 Results 
Demographic Characteristics 
Table 4.2 shows that there were 22,212 patients, out of which 7,476 (33.66%) were long-
term opioid users and 14,736 (66.34%) were short-term opioid users. The mean age for patients 
with long-term opioid use was 55.82 ± 7.87 years and mean age for patients with short-term opioid 
usage was 53.13±6.52 years. The majority of long-term opioid users were males (53.04%) whereas 
most short-term opioid users were females (52.69%). Mean non-diabetes severity reported through 
the elixhauser index was 0.12 ± 1.10 for long-term opioid users, and it was 0.13 ± 1.06 for short-
term users. Mean diabetes severity was 0.08 ± 0.37 for long-term opioid users and 0.08 ± 0.32 for 
short-term opioid users. The majority of patients in both groups were on non-capitated plans. 
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Table 4.2 Frequency and distribution of patient demographics  
 Long-term opioid users Short-term opioid users P-Value 
 N = 7,476 N = 14,736  
 Mean SD Mean SD  
Age, years 55.82 7.87 53.13 6.52 <0.0001 
Clinical characteristics  
aElixhauser indexa 0.12 1.10 0.13 1.06 <0.0001 
aDCSIb 0.08 0.37 0.08 0.32 <0.001 
  
 N % N %  
Gender  
Male 3,965 53.04 6,971 47.31 <0.0001 
Female 3,511 46.96 7,765 52.69 <0.0001 
Region  
Northeast 581 7.77 673 4.57 <0.0001 
North Central 2,650 35.45 4,354 29.55 <0.0001 
South 2,579 34.50 7,098 48.17 <0.0001 
West 1,666 22.28 2,519 17.72 <0.0001 
Insurance plan type  
Basic and comprehensive 
plans 1,904 25.47 2,567 17.42 <0.0001 
Capitated plan 2,629 35.17 4,886 33.14 <0.0001 
Non-capitated plan 2,916 39.00 7,246 49.17 <0.0001 
CDHP and HDHPc 27 0.36 40 0.27 <0.0001 
Presence of Capitated Payment  
Capitated 11,77 15.74 1,489 10.12 <0.0001 
Non-capitated 6,299 84.26 13,230 89.88 
<0.0001 
a Adapted Elixhauser Index     
bAdapted diabetes severity comorbidity index 
c Consumer-Driven Health Plan/High Deductible Health plan 
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Multivariable Cox Proportional Hazard Regression Analysis 
Extended cox proportional hazard model was fit to determine the subsequent risk of 
T2DM related hospitalization among patients with T2DM who were prescribed 
antihyperglycemic medications and prescription opioids concomitantly. Two separate models 
were executed to measure the subsequent T2DM medication, with and without the mediation 
effect of follow up antihyperglycemic adherence. 
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Extended Cox proportional hazard analysis to estimate T2DM related hospitalizations without 
follow up antihyperglycemic adherence 
 
Figure 4.3 Kaplan Meier curve to estimate T2DM related hospitalizations without follow up 
antihyperglycemic adherence 
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Findings from Table 4.3 show that risk of T2DM related hospitalization was less among 
long-term opioid users with 150 days or less of follow-up (HR = 0.80, 95% CI = 0.75-0.85) as 
compared to short-term opioid users. T2DM related hospitalization risk among long-term opioid 
users in greater than 150 days of follow-up (HR = 0.88, 95% CI = 0.52-1.49) as compared to 
short-term opioid users. Females (HR = 1.02, 95% CI = 0.97-1.08) were more likely to have 
T2DM related hospitalizations as compared to males. Patients in the age group of 31to 45 years 
(HR = 1.46, 95% CI = 1.07- 1.98), 46 to 60 years (HR = 1.52, 95% CI = 1.13 – 2.05) and 
patients above 60 years (HR = 1.52, 95% CI = 1.12 – 2.05) have higher risk of T2DM related 
hospitalizations as compared to patients in the age group of 18 to 30 years. Hospitalization risk 
increase significantly among patients with prior T2DM related hospitalization. 
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Table 4.3 Cox proportional hazard regression to study predictors of T2DM related 
hospitalizations without follow up antihyperglycemic adherence 
Analysis of Maximum Likelihood Estimates 
Parameter Parameter Estimate 
Hazard 
Ratio 
95% 
Confidence 
Limits 
P Value 
Opioid use (Ref = Short-term opioid use) 
Long-term opioid use (less than equal to 150 
days) -0.22 0.80 0.75 0.85 <.0001 
Long-term opioid use (greater than 150 and 
less than equal to 180 days) -0.13 0.88 0.52 1.49 0.63 
Gender (Ref = Male) 
Female 0.02 1.02 0.97 1.08 0.40 
Region (Ref = Northeast) 
North central 0.03 1.03 0.91 1.17 0.67 
South 0.18 1.20 1.06 1.36 0.003 
West 0.12 1.13 0.97 1.32 0.12 
Age Category (Ref = 18 – 30 years) 
31- 45 years 0.38 1.46 1.07 1.98 0.02 
46- 60 years 0.42 1.52 1.13 2.05 0.01 
Greater than 60 years 0.42 1.52 1.12 2.05 0.01 
Health Plan Type (Ref = Basic and comprehensive plans) 
Non capitated plan 0.06 1.06 0.97 1.16 0.23 
Capitated plans 0.07 1.07 0.99 1.16 0.09 
CDHP and HDHPa -0.24 0.79 0.44 1.43 0.44 
Non diabetes severity index 
aElixhauser Indexb -0.03 0.97 0.96 0.99 0.001 
 Diabetes severity Index 
aDCSIc 0.03 1.03 0.97 1.09 0.34 
Prior hospitalization history 
Prior hospitalization 2.56 12.90 11.98 13.90 <.0001 
Baseline antihyperglycemic adherence 
Baseline antihyperglycemic adherence 0.33 1.40 1.25 1.56 <.0001 
Capitated service (Ref = No) 
Yes -0.21 0.81 0.70 0.93 0.00 
a Consumer-Driven Health Plan and High Deductible Health plan 
b adapted Elixhauser Index    
c Adapted diabetes severity comorbidity index 
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Extended Cox proportional hazard analysis to estimate T2DM related hospitalizations with 
follow up antihyperglycemic adherence 
Figure 4.4 Kaplan Meier curve to estimate T2DM related hospitalizations with follow up 
antihyperglycemic adherence 
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Findings from Table 4.4 show that risk of T2DM related hospitalization was lower among 
patients with long-term opioid use with 150 days or less of follow-up (HR = 0.73, 95% CI = 0.69-
0.78) as compared to short-term users. Whereas, among patients with long-term opioid use greater 
than 150 days (HR = 1.25, 95% CI = 0.69-2.28), risk of T2DM related hospitalizations increased 
as compared to short-term opioid users however, it was not significant. Females (HR = 1.02, 95% 
CI = 0.97-1.08) were more likely to have T2DM related hospitalizations as compared to males. 
Patients in age group of 31 to 45 years (HR = 1.27, 95% CI = 0.91- 1.78), 46 to 60 years (HR = 
1.27, 95% CI = 0.92 – 1.76) and patients above 60 years (HR = 1.24, 95% CI = 0.89 – 1.72) had 
higher risk of T2DM related hospitalizations as compared to patients in age group of 18 to 30 
years. Hospitalization risk increased significantly among patients with prior T2DM related 
hospitalization. Follow up antihyperglycemic adherence (HR = 1.44, 95% CI = 1.25 – 1.64) was a 
significant predictor of T2DM related hospitalization. 
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Table 4.4 Cox proportional hazard regression to study predictors of T2DM related 
hospitalizations with follow up antihyperglycemic adherence as a mediator 
Analysis of Maximum Likelihood Estimates 
Parameter Parameter Estimate 
Hazard 
Ratio 
95% 
Confidence 
Limits 
P Value 
Opioid use (Ref = Short-term opioid use) 
Long-term opioid use (less than equal to 150 
days) -0.32 0.73 0.69 0.78 <.01 
Long-term opioid use (greater than 150 and 
less than equal to 180 days) 0.22 1.25 0.69 2.28 0.47 
Gender (Ref = Male) 
Female 0.02 1.02 0.97 1.08 0.45 
Region (Ref = Northeast) 
North central -0.01 0.99 0.87 1.13 0.86 
South 0.15 1.17 1.03 1.32 0.02 
West 0.09 1.09 0.93 1.28 0.27 
Age Category (Ref = 18 – 30 years) 
31- 45 years 0.24 1.27 0.91 1.78 0.16 
46- 60 years 0.24 1.27 0.92 1.76 0.15 
Greater than 60 years 0.21 1.24 0.89 1.72 0.21 
Health Plan Type (Ref = Basic and comprehensive plans) 
Non capitated plan 0.06 1.06 0.97 1.17 0.18 
Capitated plans 0.08 1.09 1.00 1.18 0.04 
CDHP and HDHPa -0.20 0.82 0.45 1.49 0.52 
Non diabetes severity index 
aElixhauser Indexb -0.01 0.99 0.97 1.01 0.26 
Diabetes severity Index 
aDCSIc 0.03 1.03 0.97 1.09 0.34 
Prior hospitalization history 
Prior hospitalization 2.56 12.90 11.98 13.90 <.01 
Baseline antihyperglycemic adherence 
Baseline antihyperglycemic adherence 0.14 1.16 1.02 1.31 0.02 
Capitated service (Ref = No) 
Yes -0.21 0.81 0.70 0.94 0. 04 
Follow-up antihyperglycemic adherence 
Follow up antihyperglycemic adherence 0.36 1.44 1.25 1.64 <.01 
a Consumer-Driven Health Plan and High Deductible Health plan 
b adapted Elixhauser Index     
c Adapted diabetes severity comorbidity index 
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4.8 Discussion 
Prescription opioids are considered the most effective medication class for the management 
of chronic pain. However, there is limited evidence to support long-term use of opioids for pain 
management, due to concerns related regarding negative effects which includes ADRBs, which 
can potentially affect antihyperglycemic medication adherence. As seen in the results, without 
taking antihyperglycemic adherence into account, short-term users were more likely to have 
T2DM related hospitalizations. With follow-up antihyperglycemic adherence being accounted for, 
short- term users still were at a higher risk of T2DM related hospitalizations. The risk increased 
among long-term opioid users with the follow-up antihyperglycemic adherence, but it was not 
statistically significant. This reversal in pattern among long-term opioid users cannot conclude any 
negative impact of long-term opioid use on T2DM related hospitalizations. Future studies are 
needed in specific age populations to study any potential impact of ADRBs. In this study, lower 
hospitalization rates may be associated with patients, better managing their painful conditions, 
which leads to better management of their T2DM. Thus in turn leads to a lower risk for T2DM 
related hospitalizations.  
There are a few limitations related to this study. Administrative claims data used for this 
study is collected for billing and reimbursement purposes by health care plans and may not be well 
suited for research purposes. Therefore, generating causal inferences from this study is not 
appropriate. Also, claims data often has data entry errors. Additionally, calculation for adherence 
(PDC) is based on days supplied and service dates, but it cannot be determined if the patient 
actually ingested the prescription medication. This database does not record cash payments, which 
is often the mode of payment among abusers who buy prescription opioids, instead of using their 
insurance. Also, the database used for this study is from 2003 -2004, thus limiting any new 
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medications approved after the study period. Finally, this data is limited to individuals on 
commercial health insurance plans; hence the findings from the study cannot be generalizable to 
the entire US population. 
4.9 Conclusion 
Short-term opioid use is associated with higher T2DM related hospitalization risks. To 
study the effects of long-term use and ADRBs among patients where antihyperglycemic and 
prescription opioids are concomitantly prescribed, future studies are needed with long-term 
follow-up among specific age categories where prescription opioid utilization rates are higher.  
 
 
 
 
 
 
 
 
 
63 
 
Executive Summary 
 Prescription opioids when prescribed concomitantly with antihyperglycemic medication 
adherence do not a demonstrate decrease in antihyperglycemic medication, and long-term opioid 
use is not associated with increased T2DM hospitalization risk.  
Long-term use of prescription opioids and its negative consequences are well documented. 
Even though the current study was not able to establish any negative consequences regarding 
concomitant prescription opioid use on antihyperglycemic medication adherence, future studies 
are needed with a longer follow-up duration among patients with continuous opioid use of six 
months or greater.  
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